Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program
- PMID: 29958128
- PMCID: PMC6139651
- DOI: 10.1016/j.drugalcdep.2018.05.010
Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program
Abstract
Background: Guidelines recommend long-term treatment for opioid use disorder including the use of buprenorphine; however, many patients desire to eventually taper off. This study examines the prevalence and patient characteristics of patients that voluntarily taper off buprenorphine.
Methods: This is a 12-year retrospective cohort study of adults on buprenorphine in a large urban safety-net primary care practice. The primary outcome was completion of a voluntary buprenorphine taper, which was further characterized as a medically supervised or unsupervised taper. The secondary outcome was re-engagement in care after taper. Descriptive statistics and estimated proportions of both taper completion and re-engagement in treatment were calculated using Kaplan-Meier estimates.
Results: The study sample included 1308 patients with a median follow-up time of 316 days; 48 patients were observed to taper off buprenorphine during the study period, with an estimated proportion of 15% (95%CI: 10%-21%) based on Kaplan Meier analyses. Less than half of the tapers, 45.8% (22/48), were medically supervised. Thirteen of the 48 patients subsequently, re-engaged in buprenorphine treatment (estimated proportion 61%, 95%CI: 27%-96%), based on Kaplan-Meier analyses with median follow-up time of 490 days.
Discussion: Despite the fact that many patients desire to discontinue buprenorphine, a minority had a documented taper. Among those who tapered, more than half did so unsupervised by the clinic and a majority of those who tapered off returned to buprenorphine treatment within two years. As many patients are unable to successfully taper off buprenorphine, the medical community must work to address any barriers to long-term maintenance.
Keywords: Buprenorphine; Opioid use disorder; Patient dropout.
Copyright © 2018 Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of Interest
No conflict declared.
Similar articles
-
Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302. JAMA Intern Med. 2014. PMID: 25330017 Free PMC article. Clinical Trial.
-
Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.Addiction. 2017 Jul;112(7):1202-1209. doi: 10.1111/add.13782. Epub 2017 Feb 28. Addiction. 2017. PMID: 28164407 Free PMC article.
-
Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.J Gen Intern Med. 2017 Jun;32(6):660-666. doi: 10.1007/s11606-017-3993-2. Epub 2017 Feb 13. J Gen Intern Med. 2017. PMID: 28194688 Free PMC article. Clinical Trial.
-
Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.Rural Remote Health. 2015;15:3019. Epub 2015 Feb 4. Rural Remote Health. 2015. PMID: 25651434 Review.
-
Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.Adolesc Med State Art Rev. 2014 Aug;25(2):251-65. Adolesc Med State Art Rev. 2014. PMID: 27132312 Review. No abstract available.
Cited by
-
Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration.Drug Alcohol Depend. 2023 Jul 1;248:109902. doi: 10.1016/j.drugalcdep.2023.109902. Epub 2023 May 2. Drug Alcohol Depend. 2023. PMID: 37196572 Free PMC article.
-
A Research Agenda for Advancing Strategies to Improve Opioid Safety: Findings from a VHA State of the Art Conference.J Gen Intern Med. 2020 Dec;35(Suppl 3):978-982. doi: 10.1007/s11606-020-06260-9. Epub 2020 Nov 3. J Gen Intern Med. 2020. PMID: 33145681 Free PMC article.
-
Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.Am J Addict. 2019 Jul;28(4):270-276. doi: 10.1111/ajad.12884. Epub 2019 Apr 16. Am J Addict. 2019. PMID: 30993833 Free PMC article.
-
Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.JAMA Netw Open. 2022 Sep 1;5(9):e2234168. doi: 10.1001/jamanetworkopen.2022.34168. JAMA Netw Open. 2022. PMID: 36173629 Free PMC article.
-
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.Am J Addict. 2020 Jul;29(4):313-322. doi: 10.1111/ajad.13024. Epub 2020 Apr 4. Am J Addict. 2020. PMID: 32246728 Free PMC article. Clinical Trial.
References
-
- Amato L, Minozzi S, Davoli M, Vecchi S, 2011. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification, in: Cochrane Database of Systematic Reviews. John Wiley and Sons, Ltd. - PubMed
-
- Appel PW, Ellison AA, Jansky HK, Oldak R, 2004. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: Opinions of drug injecting street outreach clients and other system stakeholders. Am. J. Drug Alcohol Abuse 30, 129–153. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials